Gepasol-Neo is a drug (a solution of amino acids) that takes part in metabolic processes and has a detoxification and hepatoprotective effect. Designed for parenteral nutrition in patients with liver failure.
Release form and composition
Dosage form of the drug - 8% infusion solution.
Composition 1 liter Gepasol-Neo:
- 880 mg of L-phenylalanine;
- 700 mg of acetylcysteine, which corresponds to 520 mg of L-cysteine;
- 700 mg of L-tryptophan;
- 13.09 g L-leucine
- 10.72 g L-arginine;
- 10.08 g L-valine;
- 10.4 g L-isoleucine;
- 9.71 g of L-lysine monoacetate, which corresponds to 6.88 g of L-lysine;
- 5.82 g of glycine;
- 5.73 g L-proline
- 4.64 g of L-alanine;
- 4.4 g L-threonine;
- 2.8 g of L-histidine;
- 2.24 g of L-serine;
- 1.1 g of L-methionine;
- Auxiliary components: glacial acetic acid and injectable water (up to 1 liter).
The energy value is 320 kcal / l (1344 kJ / l), osmolarity - 770 mOsm / l, pH– 5.7–6.3.
Implemented Gepasol-Neo 500 ml in glass bottles complete with plastic holder.
Indications for use
The preparation contains amino acids, of which 8 are essential, 2 conditionally replaceable, but which under certain pathophysiological conditions are synthesized in an insufficient quantity, and 5 replaceable, which provide an adequate metabolism. All of these amino acids are in the L-form, so they are directly involved in the biosynthesis of proteins. Thus, Gepasol-Neo allows to correct the amino acid disorders caused by liver failure. In addition, this drug helps to significantly improve the tolerability of proteins in patients with hepatitis and cirrhosis of the liver, as well as reduces the severity of symptoms of hepatic encephalopathy.
Given these properties of Gepasol-Neo, the drug is prescribed for:
- Therapy of hepatic coma and pre-comatose states;
- Therapy and parenteral nutrition (full or partial) for liver failure, including hepatic encephalopathy.
The use of Gepasol-Neo, according to the instructions, is contraindicated in:
- Violation of the metabolism of amino acids;
- Renal failure;
- Decompensated heart failure.
Also, the drug is prohibited:
- Children and teenagers under 18;
- In case of hypersensitivity to any component of the drug;
- Breastfeeding women;
- During lactation.
Dosing and Administration
Specific dosages in each case are set individually, taking into account the severity of the disease and the concentration of ammonia in the blood.
Solution Gepasol-Neo is intended for intravenous drip infusion. The rate of injection is calculated based on the patient's weight - 1-1.25 ml per kilogram of body weight per hour (approximately 30-35 drops per minute), which corresponds to 0.08-0.1 gram of amino acids / kg / hour.
The maximum daily dose of the drug is 18.75 ml / kg (1.5 grams of amino acids / kg per day), i.e. for a patient with a body weight of 70 kg, it will be 1300 ml.
The duration of Gepasol-Neo is determined by the complete disappearance of neurological symptoms.
According to the instructions to Gepasol-Neo, when used at recommended doses, the drug has no side effects.
With a significant excess of therapeutic dosages possible: fever, nausea, vomiting, tachycardia, increased sweating, an increase in the concentration of residual nitrogen and increased activity of liver enzymes. Exceeding the recommended rate of drug administration can lead to peripheral edema, hyperhydration and even pulmonary edema.
The specific antidote Gepasol-Neo does not exist. In case of overdose, you should immediately stop the infusion and prescribe symptomatic treatment.
Gepasol-Neo can be used only in a hospital in medical institutions!
During the period of drug treatment, it is necessary to regularly monitor the state of kidney function, the degree of hydration of the body, electrolyte and acid-base status.
Hepasol-Neo is pharmacologically incompatible with the following antibiotics: vancomycin, tobramycin, tetracycline, erythromycin, chloramphenicol, piperacillin, netilmicin, cefotaxime, amikacin, penicillin, ceftriaxone, clindamycin, and cefoxime, amikacin, penicillin, ceftriaxone, clindamycin, and cefoxime, amikacin, penicillin, ceftriaxone, clindamycin, and cefoxime, amikacin, penicillin, ceftriaxone, clindamycin, and cefoxime.
It is forbidden to use Gepasol-Neo with Calcium , nizatidine, heparin, fluorouracil, famotidine, cimetidine.
Many other Gepasol-Neo in vitro interactions are known, therefore no other drugs are recommended to be added to the solution.
With the same composition as Gepasol-Neo, the following drugs are available: Aminoven, Aminodez, Aminoven Infant, Aminosol-Neo, Aminoplasmal Gepa, Aminosteril N-Gepa, Aminosteril KE Nefro, Aminotrof, Gidrolizina solution, Diphpivin, Aminosteril KE Nefro, Aminotrof, Hydrolysine, Gepa, Aminosteril KE Nefro, Aminotrof, Gida, Aminoternil N-Gepa Fibrinosol, Hymix.
The same pharmacological subgroup (“Preparations for parenteral nutrition”) includes the following solutions for infusion / intravenous administration: Aminokrovin, Aminoplasmal (E5, E10 and E15), Aminoplasma B. Brown (E5 and E 10), Aminosol-Neo E, Aminosteryl KE, Gepasol A, Hydramine, Glucose, Glucose Brown, Glucose-E, Glucosteril, Glucose-Eskom, Dextrose, Intralipid, Infesol, Infusamin, Kabiven, Lipofundin MCT / LST, Lipoplus 20, Nutriflex, Omericlimer, Limestone, Lipofundin MST / LST, Lipoplus 20, Nutriflex, Omericlimer, Limestone, Lipofundin
Terms and conditions of storage
Gepasol-Neo - prescription drug. The shelf life of the solution is 2 years if it is stored in accordance with the recommendations of the manufacturer - at a temperature of 15-25 ºС in a dark place.